SoftBank Group CEO Masayoshi Son revealed at a press conference on June 27th that SoftBank has established a joint venture with Tempus AI, a Japanese technology company, to use artificial intelligence (AI) to analyze personal medical data and provide treatment recommendations.

Tempus AI is a precision medical technology company in the United States committed to providing advanced data and analysis tools for the global medical care field. Its core business is genome testing services.

At the press conference, Son said that SoftBank and Tempus AI hope to bring AI treatment recommendations and clinical trial recommendations to the Japanese market, making Japan another medical care market that can provide such services outside the United States.

According to the company's press release on the same day, SoftBank and Tempus will each invest 15 billion yen (about $93 million) in the joint venture, which is expected to be completed in July.

In April of this year, SoftBank invested about $200 million in Tempus's G round of financing. Tempus went public on Nasdaq this month, with an initial offering price of $37 on June 14. As of Wednesday (June 26th) closing, its stock price had fallen to around $27.50.

This is the latest in a series of artificial intelligence investments recently announced by SoftBank. After a few years of silence, SoftBank has accelerated its investment activities.

According to sources, SoftBank Vision Fund 2 will invest $10-20 million in American search startup Perplexity AI, valued at $3 billion overall.

Perplexity, which is a major competitor of Google's search engine, was established less than two years ago. The service it provides is called the "answer engine," which replies to users in text format rather than links.

The company raised $73.6 million from Nvidia and Amazon founder Bezos in January this year, valued at $520 million at the time. SoftBank's potential investment highlights SoftBank's ambitions in the field of artificial intelligence.